Our commitments

Protecting Lives

We invest in R&D to develop best in class vaccines for unmet medical needs, prioritizing universal access and improving trust in vaccine safety.

• By 2026, we want to enable access to Valneva’s single-shot chikungunya vaccine in India and Brazil by enabling local manufacturing and access through technology transfers. In Asia we signed an exclusive license agreement with the Serum Institute of India (SII), complementing our existing agreement with Instituto Butantan in the Americas.

Reaching People

We rely on a workforce that is diverse, engaged and committed to ethical practices and equipped with essential skills.

• We are proud that all our employees have participated in performance and career reviews and 58% of our workforce is made up of women.

Preserving the Planet

We emphasize the importance of maintaining a low carbon footprint, minimizing the company´s environmental impact, promoting animal welfare and the assessment of new components and material compositions.

• Valneva has 100% green electricity at its R&D and manufacturing sites. In 2024, we used 17% less water than in 2023 and recycled 65% of waste.